Skip to main content

Advertisement

SpringerLink
Log in

Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Nowadays, 40 % of early-stage NSCLC patients relapse in the 2 years following resection, suggesting a mis-staging in this group of patients who are not receiving adjuvant chemotherapy. Although different biomarkers, such as ERCC1, RRM1 and BRCA1 have been found to present prognostic value in advanced NSCLC patients, in early-stage NSCLC patients its relevance remains unclear. Moreover, SETDB1 has been recently proposed as a bona fide oncogene in lung tumourigenesis and related with metastasis. The aim of the present study was to analyze the prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 expression levels in NSCLC patients at stage I.

Patients and methods

ERCC1, RRM1, BRCA1 and SETDB1 expression at mRNA level was analyzed by real-time quantitative RT-PCR in fresh-frozen tumor and normal adjacent lung tissue samples from 64 stage I NSCLC patients. Later, significant association between gene expression levels, clinicopathological characteristics and patient’s disease-free survival was assessed.

Results

We did not find any statistically significant correlation between gene expression and gender, age, histological type or smoking status. Univariate followed by multivariate Cox analysis showed that higher levels of BRCA1 and SETDB1 expression were significantly associated with shorter disease-free survival in stage I NSCLC patients.

Conclusion

Our study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I NSCLC patients. By contrast, BRCA1 and SETDB1 stand out as the most significant prognostic markers in this group of patients, appearing as promising tools to predict tumor recurrence in early-stage NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cancer. WHO. Fact sheet No. 297. Updated November 2014. http://www.who.int/mediacentre/factsheets/fs297/en. Accessed 7 Jan 2015.

  2. Han Y, Wang XB, Xiao N, Liu ZD. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(5):2987–90.

    Article  PubMed  Google Scholar 

  3. Gilmore DM, Khullar OV, Jaklitsch MT, Chirieac LR, Frangioni JV, Colson YL. Identification of metastatic nodal disease in a phase 1 dose-escalation trial of intraoperative sentinel lymph node mapping in non-small cell lung cancer using near-infrared imaging. J Thorac Cardiovasc Surg. 2013;146:562–70.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Jakobsen JN, Santoni-Rugiu E, Ravn J, Sørensen JB. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer. 2013;49:2494–503.

    Article  CAS  PubMed  Google Scholar 

  5. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichlorocyclohexylamineplatinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 1999;59:3968–71.

    CAS  PubMed  Google Scholar 

  6. Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818–25.

    Article  CAS  PubMed  Google Scholar 

  7. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer. 2013;82:324–9.

    Article  PubMed  Google Scholar 

  8. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–91.

    CAS  PubMed  Google Scholar 

  9. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127:978–83.

    Article  PubMed  Google Scholar 

  10. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66:6497–502.

    Article  CAS  PubMed  Google Scholar 

  11. Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and taxol-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Cancer Res. 2013;32:15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2014;33(21):2807–13.

    Article  CAS  PubMed  Google Scholar 

  13. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471:513–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32(11):2858–68.

    Article  CAS  PubMed  Google Scholar 

  15. Sun Y, Wei M, Ren SC, Chen R, Xu WD, Wang FB, et al. Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion. Asian J Androl. 2014;16:319–24.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–7.

    Article  CAS  PubMed  Google Scholar 

  18. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small cell lung cancer. J Clin Oncol. 2004;22:1878–85.

    Article  CAS  PubMed  Google Scholar 

  19. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag Res. 2013;5:327–36.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60(3):401–7.

    Article  PubMed  Google Scholar 

  21. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356(8):800–8.

    Article  CAS  PubMed  Google Scholar 

  22. Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, et al. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res. 2012;32(11):5003–10.

    CAS  PubMed  Google Scholar 

  23. Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009;27(34):5808–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2:e1129.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gachechiladze M, Uberalla I, Kolek V, Klein J, Krejci V, Stastna J, et al. Correlation between BRCA1 expression and clinicopathological factors including brain metastases in patients with non-small-cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(3):227–32.

    CAS  PubMed  Google Scholar 

  26. Noh HJ, Kim KA, Kim KC. p53 down-regulates SETDB1 gene expression during paclitaxel induced-cell death. Biochem Biophys Res Commun. 2014;446(1):43–8.

    Article  CAS  PubMed  Google Scholar 

  27. Lee JK, Kim KC. DZNep, inhibitor of S-adenosyl homocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys Res Commun. 2013;438(4):647–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant of the Comisión de Investigación del Hospital Universitario de la Ribera (2013).

Author information

Authors and Affiliations

  1. Servicio de Genética-Biología Molecular, Hospital Universitario de la Ribera, ctra. Corbera, km.1, 46600, Alzira, Spain

    A. Lafuente-Sanchis & Á. Zúñiga

  2. Servicio de Cirugía Torácica, Hospital Universitario de la Ribera, ctra. Corbera, km.1, 46600, Alzira, Spain

    J. M. Galbis, M. Estors & N. J. Martínez-Hernández

  3. Servicio de Anatomía Patológica, Hospital Universitario de la Ribera, ctra. Corbera, km.1, 46600, Alzira, Spain

    A. Cremades

  4. Departament de Fisiologia, Facultat de Farmàcia, Universitat de València, Avda. Vicent Andrés Estellés, s/n, 46100, Burjassot, Valencia, Spain

    J. Carretero

Authors
  1. A. Lafuente-Sanchis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Á. Zúñiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Galbis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Cremades
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Estors
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. J. Martínez-Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Carretero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Lafuente-Sanchis.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lafuente-Sanchis, A., Zúñiga, Á., Galbis, J.M. et al. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer. Clin Transl Oncol 18, 798–804 (2016). https://doi.org/10.1007/s12094-015-1440-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1440-6

Keywords

Search

Navigation